These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2019 related articles for article (PubMed ID: 22236411)
1. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411 [TBL] [Abstract][Full Text] [Related]
2. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Pinelli NR; Hurren KM Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278 [TBL] [Abstract][Full Text] [Related]
4. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials. Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423 [TBL] [Abstract][Full Text] [Related]
5. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845 [TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes. Ottney A Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759 [TBL] [Abstract][Full Text] [Related]
9. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials. Su N; Li Y; Xu T; Li L; Kwong JS; Du H; Ren K; Li Q; Li J; Sun X; Li S; Tian H Int J Cardiol; 2016 Sep; 219():293-300. PubMed ID: 27343423 [TBL] [Abstract][Full Text] [Related]
10. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359 [TBL] [Abstract][Full Text] [Related]
11. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Katout M; Zhu H; Rutsky J; Shah P; Brook RD; Zhong J; Rajagopalan S Am J Hypertens; 2014 Jan; 27(1):130-9. PubMed ID: 24263424 [TBL] [Abstract][Full Text] [Related]
12. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L; Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413 [TBL] [Abstract][Full Text] [Related]
13. Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists. Lindamood CA; Taylor JR Clin Ther; 2015 Mar; 37(3):483-93. PubMed ID: 25659912 [TBL] [Abstract][Full Text] [Related]
14. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide. Guo XH Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329 [TBL] [Abstract][Full Text] [Related]
15. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305 [TBL] [Abstract][Full Text] [Related]
16. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus]. Camafort-Babkowski M Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622 [TBL] [Abstract][Full Text] [Related]
17. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Madsbad S Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):463-77. PubMed ID: 19748064 [TBL] [Abstract][Full Text] [Related]
18. Utility of GLP-1R agonists in diabetes requires long term study. de Oliveira JM BMJ; 2012 Feb; 344():e1451; author reply e1459. PubMed ID: 22374904 [No Abstract] [Full Text] [Related]
19. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461 [TBL] [Abstract][Full Text] [Related]